Updates from the PROpel and MAGNITUDE studies

Bookmark and Share
Published: 11 Jul 2022
Views: 1261
Prof Phil Cornford and Dr Elena Castro

Prof Phil Cornford (Royal Liverpool University Hospital, Liverpool, UK) and Dr Elena Castro (Spanish National Cancer Research Center, Madrid, Spain) discuss the updates from PROPEL and MAGNITUDE studies.

Initially, Dr Castro explains the background and methodology of the PROpel study and mentions the results. She discusses the tolerability of abiraterone combined with olaparib in patients with metastatic castration-resistant prostate cancer.

Prof Cornford and Dr Castro also talk about the health-related quality of life (HRQoL) and pain in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients with metastatic castration-resistant prostate cancer and homologous recombination repair (HRR) gene alterations.

They conclude by comparing the differences between different available PARP inhibitors and what is available in Europe.

This programme has been supported by an unrestricted educational grant from AstraZeneca.